Corvus Pharmaceuticals, Inc

(NASDAQ:CRVS)

Latest On Corvus Pharmaceuticals, Inc (CRVS):

Date/Time Type Description Signal Details
2023-05-12 22:21 ESTNewsCorvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma MarketN/A
2023-05-08 22:39 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.17 misses by $0.01N/A
2023-05-08 22:39 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) Q1 2023 Earnings Call TranscriptN/A
2023-05-07 20:51 ESTNewsCorvus Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-29 11:09 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call TranscriptN/A
2023-03-28 20:35 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.21 beats by $0.02N/A
2022-11-07 01:12 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call TranscriptN/A
2022-11-04 01:21 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.32 misses by $0.16N/A
2022-11-03 07:35 ESTNewsCorvus Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-09-26 18:13 ESTNewsCorvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in ChinaN/A
2022-08-09 00:57 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.18 in-lineN/A
2022-08-09 00:56 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-06 08:07 ESTNewsCorvus Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-05-06 01:39 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.18N/A
2022-03-11 09:34 ESTNewsCorvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01N/A
2022-03-11 09:34 ESTNewsCorvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-09 22:06 ESTNewsCorvus Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-01-14 06:28 ESTNewsCorvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in ChinaN/A
2021-12-11 08:34 ESTNewsChecking In On Corvus PharmaceuticalsN/A
2021-11-01 17:42 ESTNewsCorvus Pharmaceuticals EPS misses by $0.03N/A
2021-09-24 02:10 ESTNewsCorvus Pharmaceuticals: More Than A CD73 Sympathy PlayN/A
2021-09-23 00:42 ESTNewsCorvus: Surging On AstraZeneca CD73 Success With Key Data Readout LoomingN/A
2021-09-21 15:24 ESTNewsAstraZeneca lung cancer data propel Corvus and ArcusN/A
2021-09-21 15:23 ESTNewsCRVS, APRE, GDS and OYST among after hours moversN/A
2021-09-21 15:23 ESTNewsCorvus Pharma has stellar day closing 135% higher; reaches 52-week high after-hoursN/A
2021-09-21 15:20 ESTNewsAPRE, GMAB, VRCA and CRVS among after hours moversN/A
2021-09-21 15:18 ESTNewsCorvus Pharma extends gains to more than double in value this yearN/A
2021-08-17 11:34 ESTNewsCorvus Pharma to commence Phase 1/1b trial of CPI-818 in ChinaN/A
2021-08-03 09:45 ESTNewsCorvus Pharmaceuticals EPS in-lineN/A
2021-07-21 03:20 ESTNewsCorvus Pharmaceuticals initiated buy at Cantor with a Street-high targetN/A
2021-07-21 02:29 ESTNewsCorvus shares drop after scrapping late-stage mupadolimab COVID-19 trialN/A
2021-07-21 02:28 ESTNewsCorvus Pharma praised for its focus after end to COVID-19 studyN/A
2021-03-25 12:00 ESTNewsCorvus Pharmaceuticals EPS beats by $1.16N/A
2021-03-12 22:57 ESTNewsCorvus Pharmaceuticals (CRVS) Investor Presentation - SlideshowN/A
2021-02-23 03:28 ESTAnalyst RatingThe Analyst Target Price has increased from $8.6 to $9.25.Buy
2021-02-20 01:27 ESTNewsCorvus Pharma surges after an insider purchase of ~1.3M sharesN/A
2021-02-17 19:28 ESTNewsCorvus closes 8.6M share public offeringN/A
2021-02-12 16:58 ESTNewsCorvus shares slide after pricing 8.57M public offeringN/A
2021-02-11 23:25 ESTNewsCorvus Pharma announces proposed public offeringN/A
2021-02-11 11:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.2 to $8.6.Neutral
2021-02-11 05:12 ESTNewsCorvus cut to neutral at Mizuho citing realignment of pipelineN/A
2021-01-20 16:29 ESTNewsCorvus Pharmaceuticals: Undervalued Based On COVID-19 Opportunity And Oncology AssetsN/A
2020-12-13 03:43 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 10:46 ESTNewsCorvus' immunotherapy shows durable benefit in COVID-19N/A
2020-11-07 15:30 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 06:14 ESTNewsSeeking Alpha Catalyst WatchN/A
2020-11-02 17:03 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.6 to $9.2.Neutral
2020-11-01 23:28 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 20:36 ESTEarnings EstimateAn EPS average of -$0.33 is estimated for the quarter ending on March 31, 2021.N/A
2020-10-07 16:40 ESTAnalyst RatingThe Analyst Target Price has increased from $9.2 to $9.6.Buy

About Corvus Pharmaceuticals, Inc (CRVS):

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.

CRVS Quotes by TradingView

See Advanced Chart

General

  • Name Corvus Pharmaceuticals, Inc
  • Symbol CRVS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 52
  • Fiscal Year EndDecember
  • IPO Date2016-03-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.corvuspharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.95
  • Enterprise Value EBITDA 0.14
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.23
  • Return on Assets -38%
  • Return on Equity -72%
  • Earnings Per Share -$1.56
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 120.35 million
  • EBITDA -47441000
  • Analyst Target Price $9.25
  • Book Value Per Share $1.51
View More

Share Statistics

  • Shares Outstanding 37.85 million
  • Shares Float 17.12 million
  • % Held by Insiders 498%
  • % Held by Institutions 63.75%
  • Shares Short 1.27 million
  • Shares Short Prior Month 1.24 million
  • Short Ratio 0.76
  • Short % of Float 5%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.77
  • 52 Week High $5.28
  • 52 Week Low $1.91
  • 50 Day Moving Average 3.63
  • 200 Day Moving Average 3.89
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Corvus Pharmaceuticals, Inc (CRVS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Corvus Pharmaceuticals, Inc (CRVS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-10-29$N/A-$0.33-$0.22-51.72%
2020-06-302020-07-30$N/A-$0.36-$0.24-51.58%
2020-03-312020-04-30$N/A-$0.44-$0.41-8.64%
2019-12-312020-03-05$N/A-$0.38-$0.31-22.58%
2019-09-302019-10-29$N/A-$0.37-$0.4313.29%
2019-06-302019-08-01$N/A-$0.44-$0.44-0.76%
2019-03-312019-05-09$N/A-$0.40-$0.4816.05%
2018-12-312019-03-07$N/A-$0.36-$0.5028%
2018-09-302018-11-01$N/A-$0.36-$0.4926.03%
2018-06-302018-08-02$N/A-$0.40-$0.6134.16%
2018-03-312018-05-03$N/A-$0.63-$0.7718%
2017-12-312018-03-01$N/A-$0.58-$0.7724.58%
2017-09-302017-11-02$N/A-$0.62-$0.8425.82%
2017-06-302017-08-03$N/A-$0.73-$0.741.12%
2017-03-312017-05-04$N/A-$0.79-$0.77-2.6%
2016-12-312017-03-10$N/A-$0.55-$0.55-0.73%
2016-09-302016-11-03$N/A-$0.51-$0.45-13.33%
2016-06-302016-08-04$N/A-$0.43-$0.32-36.38%
2016-03-312016-05-05$N/A-$5.39-$6.0911.49%

Corvus Pharmaceuticals, Inc (CRVS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Corvus Pharmaceuticals, Inc (CRVS) Chart:

Corvus Pharmaceuticals, Inc (CRVS) News:

Below you will find a list of latest news for Corvus Pharmaceuticals, Inc (CRVS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Corvus Pharmaceuticals, Inc (CRVS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1710.5CALL1 10TRUE0.050.11
2024-05-1720.05CALL4 294116.03FALSE00
2024-05-1730CALL0 00FALSE00
2024-05-1740CALL0 00FALSE00
2024-05-1750CALL0 00FALSE00
2024-05-1710PUT0 00FALSE00
2024-05-1720.6PUT0 1124.86TRUE00
2024-05-1730PUT0 0407.09TRUE00
2024-05-1740PUT0 0386.51TRUE00
2024-05-1750PUT0 0669.46TRUE00
2024-06-2110CALL0 0123.1TRUE00
2024-06-2120.1CALL2 096.95FALSE0.10
2024-06-2130CALL0 00FALSE00
2024-06-2140CALL0 00FALSE00
2024-06-2110PUT0 00FALSE00
2024-06-2120PUT0 00TRUE00
2024-06-2130PUT0 0100.4TRUE00
2024-06-2140PUT0 0314.49TRUE00
2024-07-1910.47CALL0 87114.64TRUE00
2024-07-1920.15CALL1 20997.19FALSE00
2024-07-1930.15CALL0 840FALSE00
2024-07-1940.15CALL0 670FALSE00
2024-07-1950.05CALL0 1360FALSE00
2024-07-1910.05PUT0 40138.73FALSE00
2024-07-1920.65PUT0 55115.07TRUE00
2024-07-1931.15PUT0 7121.42TRUE00
2024-07-1940PUT0 0178.31TRUE00
2024-07-1950PUT0 0214.36TRUE00
2024-10-1810.8CALL0 26124.86TRUE00
2024-10-1820.33CALL13 193109.09FALSE0.330
2024-10-1830.12CALL0 18389.83FALSE00
2024-10-1840.05CALL10 592.67FALSE0.050
2024-10-1850.18CALL0 870FALSE00
2024-10-1810.15PUT0 12117.25FALSE00
2024-10-1820.77PUT0 72113.36TRUE00
2024-10-1831.4PUT0 4106.17TRUE00
2024-10-1840PUT0 0105.56TRUE00
2024-10-1850PUT0 0158.4TRUE00

Latest CRVS Trades:

Date Shares Price
Jun 13, 2022 7:13 PM EST45$0.9764
Jun 13, 2022 7:19 PM EST2$0.9763
Jun 13, 2022 7:20 PM EST45$0.9734
Jun 13, 2022 7:20 PM EST90$0.9733
Jun 13, 2022 7:20 PM EST100$0.9702

Corvus Pharmaceuticals, Inc (CRVS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920073458/0001104659-20-073458-index.htm
2018-08-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626971/000000000018023785/0000000000-18-023785-index.htm
2018-08-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626971/000000000018026391/0000000000-18-026391-index.htm
2020-03-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626971/000000000020002243/0000000000-20-002243-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000008025519002716/0000080255-19-002716-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000008025520001312/0000080255-20-001312-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000031506619000997/0000315066-19-000997-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017912/0000899243-18-017912-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017913/0000899243-18-017913-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017914/0000899243-18-017914-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017915/0000899243-18-017915-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318017916/0000899243-18-017916-index.htm
2018-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318030242/0000899243-18-030242-index.htm
2018-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318030539/0000899243-18-030539-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031054/0000899243-18-031054-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031055/0000899243-18-031055-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031057/0000899243-18-031057-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031058/0000899243-18-031058-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031059/0000899243-18-031059-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031061/0000899243-18-031061-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031810/0000899243-18-031810-index.htm
2018-12-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924318031989/0000899243-18-031989-index.htm
2019-01-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002186/0000899243-19-002186-index.htm
2019-01-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002187/0000899243-19-002187-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002190/0000899243-19-002190-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319002194/0000899243-19-002194-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017913/0000899243-19-017913-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017914/0000899243-19-017914-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017917/0000899243-19-017917-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017918/0000899243-19-017918-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017919/0000899243-19-017919-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319017924/0000899243-19-017924-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189519000470/0000921895-19-000470-index.htm
2019-08-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189519002114/0000921895-19-002114-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189520000529/0000921895-20-000529-index.htm
2020-02-18SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000092189520000584/0000921895-20-000584-index.htm
2019-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-07-02SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000489/0000947871-19-000489-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000571/0000947871-19-000571-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000094787119000572/0000947871-19-000572-index.htm
2020-04-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000094787120000390/0000947871-20-000390-index.htm
2018-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626971/000110465918027395/0001104659-18-027395-index.htm
2018-05-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000110465918030262/0001104659-18-030262-index.htm
2018-08-1710-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626971/000110465918052661/0001104659-18-052661-index.htm
2018-08-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626971/000110465918052664/0001104659-18-052664-index.htm
2019-05-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626971/000110465919028231/0001104659-19-028231-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000110465919062177/0001104659-19-062177-index.htm
2020-03-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626971/000110465920030827/0001104659-20-030827-index.htm
2020-03-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626971/000110465920034837/0001104659-20-034837-index.htm
2020-03-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1626971/000110465920036930/0001104659-20-036930-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920037295/0001104659-20-037295-index.htm
2020-04-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920054482/0001104659-20-054482-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000110465920073458/0001104659-20-073458-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000110465920112250/0001104659-20-112250-index.htm
2018-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000114420418035629/0001144204-18-035629-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000114420419032055/0001144204-19-032055-index.htm
2018-05-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318003466/0001171843-18-003466-index.htm
2018-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318004798/0001171843-18-004798-index.htm
2018-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318004870/0001171843-18-004870-index.htm
2018-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318005700/0001171843-18-005700-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318006835/0001171843-18-006835-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318007090/0001171843-18-007090-index.htm
2018-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318007480/0001171843-18-007480-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318007863/0001171843-18-007863-index.htm
2018-12-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184318008443/0001171843-18-008443-index.htm
2019-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000179/0001171843-19-000179-index.htm
2019-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000219/0001171843-19-000219-index.htm
2019-01-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000555/0001171843-19-000555-index.htm
2019-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319000753/0001171843-19-000753-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319001583/0001171843-19-001583-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319003207/0001171843-19-003207-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319003763/0001171843-19-003763-index.htm
2019-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319004128/0001171843-19-004128-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319005090/0001171843-19-005090-index.htm
2019-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319006916/0001171843-19-006916-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319007381/0001171843-19-007381-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319008006/0001171843-19-008006-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184319008140/0001171843-19-008140-index.htm
2020-02-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320000651/0001171843-20-000651-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320000943/0001171843-20-000943-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320001518/0001171843-20-001518-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320001878/0001171843-20-001878-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320003129/0001171843-20-003129-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320004067/0001171843-20-004067-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320004286/0001171843-20-004286-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320004791/0001171843-20-004791-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320005409/0001171843-20-005409-index.htm
2020-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320006380/0001171843-20-006380-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320006411/0001171843-20-006411-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320006493/0001171843-20-006493-index.htm
2020-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626971/000117184320007397/0001171843-20-007397-index.htm
2019-01-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000119312519023789/0001193125-19-023789-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000119312519035923/0001193125-19-035923-index.htm
2019-07-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000119312519205471/0001193125-19-205471-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626971/000119312520033205/0001193125-20-033205-index.htm
2020-07-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626971/000119312520190472/0001193125-20-190472-index.htm
2019-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2020-05-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000120919120027486/0001209191-20-027486-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2018-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837018006236/0001558370-18-006236-index.htm
2018-11-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837018008268/0001558370-18-008268-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626971/000155837019001660/0001558370-19-001660-index.htm
2019-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626971/000155837019003229/0001558370-19-003229-index.htm
2019-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626971/000155837019003232/0001558370-19-003232-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837019004697/0001558370-19-004697-index.htm
2019-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837019006824/0001558370-19-006824-index.htm
2019-10-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837019009354/0001558370-19-009354-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626971/000155837020002232/0001558370-20-002232-index.htm
2020-04-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626971/000155837020003917/0001558370-20-003917-index.htm
2020-04-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626971/000155837020003923/0001558370-20-003923-index.htm
2020-04-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837020004797/0001558370-20-004797-index.htm
2020-07-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837020008756/0001558370-20-008756-index.htm
2020-10-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626971/000155837020012039/0001558370-20-012039-index.htm
2019-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-11-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023137/0001567619-19-023137-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023139/0001567619-19-023139-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023140/0001567619-19-023140-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023143/0001567619-19-023143-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023146/0001567619-19-023146-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023147/0001567619-19-023147-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761919023148/0001567619-19-023148-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006904/0001567619-20-006904-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006905/0001567619-20-006905-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006907/0001567619-20-006907-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006908/0001567619-20-006908-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006909/0001567619-20-006909-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920006910/0001567619-20-006910-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012097/0001567619-20-012097-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012098/0001567619-20-012098-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012099/0001567619-20-012099-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012100/0001567619-20-012100-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012101/0001567619-20-012101-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920012102/0001567619-20-012102-index.htm
2020-09-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920016741/0001567619-20-016741-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626971/000156761920016744/0001567619-20-016744-index.htm
2020-03-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626971/999999999520000598/9999999995-20-000598-index.htm

Corvus Pharmaceuticals, Inc (CRVS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Corvus Pharmaceuticals, Inc (CRVS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 498%
Institutional Ownership: 6375%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-20RICHARD A MD MILLERPresident and CEOBuy5,000.004.4022,000.001,103,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-20RICHARD A MD MILLERPresident and CEOBuy5,000.004.3921,950.001,108,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031696/0000899243-18-031696-index.htm
2018-12-04RICHARD A MD MILLERPresident and CEOBuy1,502.005.958,936.901,113,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318030242/0000899243-18-030242-index.htm
2018-12-06RICHARD A MD MILLERPresident and CEOBuy5,000.005.9929,934.001,118,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318030539/0000899243-18-030539-index.htm
2018-12-27RICHARD A MD MILLERPresident and CEOBuy20,000.003.2965,884.001,128,795.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031989/0000899243-18-031989-index.htm
2019-06-07RICHARD A MD MILLERPresident and CEOBuy9,212.003.3731,018.651,138,007.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-06-11RICHARD A MD MILLERPresident and CEOBuy6,000.003.6722,020.001,144,007.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013222/0001567619-19-013222-index.htm
2019-06-13RICHARD A MD MILLERPresident and CEOBuy343.003.521,207.361,144,350.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-06-14RICHARD A MD MILLERPresident and CEOBuy11,657.003.4039,666.441,156,007.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319017182/0000899243-19-017182-index.htm
2019-08-06RICHARD A MD MILLERPresident and CEOBuy5,000.003.5817,875.001,161,007.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-08-07RICHARD A MD MILLERPresident and CEOBuy2,500.003.548,850.001,163,507.00https://www.sec.gov/Archives/edgar/data/1626971/000089924319021352/0000899243-19-021352-index.htm
2019-11-12RICHARD A MD MILLERPresident and CEOBuy272.002.90788.801,163,779.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2019-11-13RICHARD A MD MILLERPresident and CEOBuy14,736.003.0044,240.421,178,515.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919021570/0001567619-19-021570-index.htm
2020-07-08Holdings A/S Novo10% Share HolderSell741,440.005.373,985,165.861,389,498.00https://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2020-07-07Holdings A/S Novo10% Share HolderSell796,622.005.254,183,380.772,130,938.00https://www.sec.gov/Archives/edgar/data/1626971/000120919120041990/0001209191-20-041990-index.htm
2018-12-21LEIV LEAChief Financial OfficerBuy24,700.004.15102,408.6724,700.00https://www.sec.gov/Archives/edgar/data/1626971/000089924318031810/0000899243-18-031810-index.htm
2019-07-25Holdings A/S Novo10% Share HolderSell1,400,000.004.005,600,000.002,927,560.00https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-06-06LEIV LEAChief Financial OfficerBuy15,500.003.5655,180.0040,200.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-07-24Holdings A/S Novo10% Share HolderSell53,240.005.01266,711.104,327,560.00https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-07-23Holdings A/S Novo10% Share HolderSell39,716.005.32211,134.234,380,800.00https://www.sec.gov/Archives/edgar/data/1626971/000120919119043285/0001209191-19-043285-index.htm
2019-06-07LEIV LEAChief Financial OfficerBuy10,000.003.3833,800.0050,200.00https://www.sec.gov/Archives/edgar/data/1626971/000156761919013152/0001567619-19-013152-index.htm
2019-06-27ORBIMED ADVISORS LLCDirectorBuy32,923.003.34109,962.826,000,507.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-06-27Peter A. ThompsonDirectorBuy32,923.003.34109,962.826,000,507.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-06-28ORBIMED ADVISORS LLCDirectorBuy565,178.003.722,102,462.166,565,685.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-06-28Peter A. ThompsonDirectorBuy565,178.003.722,102,462.166,565,685.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-07-01ORBIMED ADVISORS LLCDirectorBuy59,243.003.91231,640.136,624,928.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000486/0000947871-19-000486-index.htm
2019-07-01Peter A. ThompsonDirectorBuy59,243.003.91231,640.136,624,928.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000487/0000947871-19-000487-index.htm
2019-08-06ORBIMED ADVISORS LLCDirectorBuy142,656.003.51500,722.566,767,584.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000571/0000947871-19-000571-index.htm
2019-08-06Peter A. ThompsonDirectorBuy142,656.003.51500,722.566,767,584.00https://www.sec.gov/Archives/edgar/data/1626971/000094787119000572/0000947871-19-000572-index.htm